BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
BioVie announced the completion of the last patient evaluation visit for its SUNRISE-PD Phase 2b trial of bezisterim in early-stage Parkinson’s disease. The study randomized 57 patients to receive either 20 mg of bezisterim or placebo twice daily over a 12-week double-blind period, with a total study duration of 20 weeks.
Key figures
- Drug Name
- bezisterim
- Phase Of Trial
- Phase 2b
- Dosage
- 20 mg twice daily
- Enrolled patients
- 60
- Randomized patients
- 57
- Study duration weeks
- 20
- Double blind duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.